About: IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes
Creator	Blasi, Francesco Tamm, Michael Torres, Antoni Welte, Tobias Egli, Adrian Lacoma, Alicia Milenkovic, Branislava Rohde, Gernot Roth, Michael Stolz, Daiana Boersma, Wim Kostikas, Kostantinos Louis, Renaud Mandal, Jyotshna Rentsch, Katharina Thomas, Brad Aerts, Joachim Schumann, Desiree Tyrrell, D
Source	Medline; PMC
abstract	BACKGROUND: Interferon lambdas (IFNLs) have important anti-viral/bacterial and immunomodulatory functions in the respiratory tract. How do IFNLs impact COPD and its exacerbations? METHODS: Five hundred twenty eight patients were recruited in a prospective observational multicentre cohort (PROMISE) study. The genetic polymorphisms (rs8099917 and rs12979860) within the IFNL3/4 gene region and circulating levels of IFNL3 in COPD patients were determined and associated with disease activity and outcome during a median follow-up of 24 months. RESULTS: The GG genotype significantly influenced severe exacerbation rate (42 vs. 23%; p = 0.032) and time to severe exacerbation (HR = 2.260; p = 0.012). Compared to the TT or TG genotypes, the GG genotype was associated with severe dyspnoea (modified medical research council score ≥ median 3; 22 vs 42%, p = 0.030). The CC genotype of the rs12979860 SNP was associated with a poorer prognosis (body mass index, airflow obstruction, dyspnea and exercise capacity index ≥ median 4; 46 vs. 36% TC vs. 20.5% TT; p = 0.031). Patients with stable COPD and at exacerbation had significantly lower circulating IFNL3 compared to healthy controls (p < 0.001 and p < 0.001, respectively). Circulating IFNL3 correlated to post-bronchodilator FEV(1)%predicted and the tissue maturation biomarker Pro-collagen 3. CONCLUSION: IFNL3/4 polymorphisms and circulating IFNL3 may be associated with disease activity and outcomes in COPD. TRIAL REGISTRATION: Clinical Trial registration http://www.isrctn.com/ identifier ISRCTN99586989 on 16 April 2008.
has issue date	2018-03-21(xsd:dateTime)
bibo:doi	10.1186/s12890-018-0616-6
bibo:pmid	29562888
has license	cc-by
sha1sum (hex)	525511c3e146527c02bc25aed2833f0ef103d62a
schema:url	https://doi.org/10.1186/s12890-018-0616-6
resource representing a document's title	IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes
has PubMed Central identifier	PMC5861655
has PubMed identifier	29562888
schema:publication	BMC Pulm Med
resource representing a document's body	covid:525511c3e146527c02bc25aed2833f0ef103d62a#body_text
is schema:about of	named entity 'COPD' named entity 'recruited' named entity 'anti-viral' named entity 'circulating' named entity 'disease' named entity 'HAVE' named entity 'STUDY' covid:arg/525511c3e146527c02bc25aed2833f0ef103d62a named entity 'PROSPECTIVE' named entity 'PATIENTS' named entity 'LOCUS' named entity 'POLYMORPHISMS' named entity 'BACKGROUND' named entity 'MEDIAN' named entity 'RS12979860' named entity 'FIVE HUNDRED' named entity 'VIRAL' named entity '24 MONTHS' named entity 'FOLLOW-UP' named entity 'ASSOCIATED WITH' named entity 'GENETIC' named entity 'DETERMINED' named entity 'IFNL3' named entity 'POLYMORPHISMS' named entity 'IMPACT' named entity 'IFN' named entity 'OUTCOMES' named entity 'CIRCULATING' named entity 'DISEASE ACTIVITY' named entity 'COHORT' named entity 'METHODS' named entity 'OUTCOME' named entity 'GENE REGION' named entity 'INTERFERON ' named entity 'COPD' named entity 'CIRCULATING' named entity 'FUNCTIONS' named entity 'IMMUNOMODULATORY' named entity 'ITS' named entity 'IMPORTANT' named entity 'RESPIRATORY TRACT' named entity 'LEVELS' named entity 'HOW' named entity 'TWENTY EIGHT' named entity 'ASSOCIATED WITH' named entity 'LEVELS' named entity 'SEVERITY' named entity 'OBSERVATIONAL' named entity 'prospective' named entity 'functions' named entity 'immunomodulatory' named entity 'COPD' named entity 'Interferon' named entity 'immunomodulatory' named entity 'gene' named entity 'respiratory tract' named entity 'IFNL3' named entity 'Interferon' named entity 'COPD' named entity 'pneumology' named entity 'virus' named entity 'serum' named entity 'genetic polymorphisms'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software